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Purpose: The fibroblast growth factor receptor 3 (FGFR3) gene is known to be frequently 
mutated in noninvasive urothelial carcinomas of the bladder. In this study, we inves-
tigated the expression of FGFR3, Ki-67, and p53 in bladder cancers and the effects of 
expression on tumor recurrence.
Materials and Methods: Fifty-five cases of primary bladder cancer were examined by 
immunohistochemistry. The relationship of these markers with various clinicopatho-
logical factors, including recurrence, was assessed.
Results: Positivity for cytoplasmic FGFR3 (FGFR3-c) was associated with a lower can-
cer grade (p=0.022) and stage (p=0.011). Recurrence was more frequent in patients with 
a higher stage, negative FGFR3-c, and high Ki-67 expression. According to univariate 
analysis, predictors of recurrence-free survival included the following: age, stage, 
FGFR-c, Ki-67, and p53. However, none of these was independent from the other param-
eters in multivariate studies.
Conclusions: The immunohistochemical expression of FGFR3 is not only one of the 
characteristic features of lower-grade and lower-stage urothelial carcinoma but also 
a possible marker in predicting disease recurrence.
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INTRODUCTION
Most bladder cancers are urothelial carcinomas, of which 
the majority (75-80%) initially present as non-muscle-in-
vasive tumors. Papillary noninvasive (pTa) and super-
ficially invasive (pT1) tumors can be treated by transure-
thral resection. However, up to 70% of patients will experi-
ence one or more recurrences and about 25% will progress 
in stage or grade of disease [1]. Therefore, patients require 
regular monitoring, which is currently performed by peri-
odic cystoscopy and urine cytology. The interval of surveil-
lance varies depending on the specific risk factors of the in-
dividual patient. Efforts have been made to clarify the sig-
nificance of various clinical and histological factors as prog-
nosticators and to develop effective risk assessment tools. 
Although some conventional factors such as number of tu-
mors, tumor size, grade, stage, and the presence of carcino-
m a  i n  s i t u  ( C I S )  h a v e  p r o g n o s t i c  p o w e r  o n  t u m o r  r e -
currence and progression [2], the ability to estimate each 
individual’s risks of adverse clinical outcome remains 
limited.
　In the ongoing search for new prognostic factors, molec-
ular markers associated with the diagnosis and the prog-
nosis of bladder cancers have been a main subject of study. 
Fibroblast growth factor receptor 3 (FGFR3) is involved in 
the regulation of proliferation, differentiation, and apopto-
sis [3]. The FGFR3 gene is known to be frequently mutated 
in noninvasive urothelial carcinomas of the bladder [4-6] 
and might correlate with better clinical outcome [7]. 
FGFR3 mRNA and protein are also reported to be overex-
pressed in a significant number of urothelial carcinomas 
of the bladder [8]. According to Tomlinson et al, the in-
creased expression of FGFR3 protein is associated with 
mutation [6], and activating mutations are frequently re-
ported and well described in the bladder cancer literature. 
However, not many studies of FGFR3 protein expression 
and its clinical significance have been carried out, although 
immunohistochemical detection of the protein is a much Korean J Urol 2010;51:94-100
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TABLE 1. Clinical and pathological data
Variables
No. of  patients
n%
Gender
　Male
　Female 
Multiplicity
　Single 
　Multiple 
Growth pattern
　Papillary
　Solid
Tumor size
　＜3 cm
　≥3 cm
Stage
　Ta
　T1
Grade
a
　PUNLMP
　Low grade
　High grade
Recurrence
　Yes
　No
40
15
44
11
50
5
35
20
38
17
10
22
23
22
33
72.7
27.3
80.0
20.0
90.9
9.1
63.6
36.4
69.1
30.9
18.2
40.0
41.8
40.0
60.0
PUNLMP: papillary urothelial neoplasm of low malignant poten-
tial, 
a: grading according to the 2004 WHO classification system
easier and simpler method to apply in the hospital-based 
setting.
　Altered p53 gene and protein status may indicate poorer 
prognoses and greater recurrences of disease [9-11]. Ki-67, 
which is strongly associated with cellular proliferation, has 
been targeted for assessing the proliferative activity of 
bladder tumor cells and correlating its expression levels 
with the prognosis of these patients. Many separate stud-
ies have shown an association between a high staining in-
dex of Ki-67 and an unfavorable disease course [12,13].
　In the present study, we examined the protein ex-
pression of FGFR3 in urothelial carcinoma of the bladder 
by immunohistochemistry. The expression levels of p53 
and Ki-67 were compared with FGFR3 immunoreactivity, 
and the relationships among these markers were inve-
stigated. Additionally, the correlations between the mark-
ers and various clinicopathological factors and between the 
markers and recurrences in bladder cancers were inves-
tigated to study the possible prognostic value of these mo-
lecular markers.
MATERIALS AND METHODS
Fifty-five cases of primary non-muscle-invasive urothelial 
carcinoma (pTa and pT1) of the bladder were included in 
this study. The patients were diagnosed and treated at one 
hospital between 2001 and 2007.
　H&E slides of all samples were reviewed, and repre-
sentative formalin-fixed paraffin-embedded tumor blocks 
were selected. Tumor staging and grading were done ac-
cording to the TNM staging system and to the 2004 WHO 
classification criteria for malignant tumors of the urinary 
tract.
　Clinical follow-up data are presented and summarized 
in Table 1. Patients ranged in age from 33 to 84 years (mean, 
67±11.3). They were followed with cystoscopy and urine cy-
tology performed every 3 months for the first 1 year, every 
6 months for the second year, and annually thereafter. The 
mean follow-up period was 26.2 months (range, 3-70 
months). Recurrence was defined as cystoscopically visible 
tumors with histologic confirmation.
　For immunohistochemistry, 5 μm deparaffinized and re-
hydrated sections were treated with 3% hydrogen peroxide 
and then microwaved for 20 minutes. The primary anti-
bodies were anti-FGFR3 (clone B-9; Santa Cruz Biotech-
nology, Inc, Santa Cruz, USA; dilution 1:100), anti-p53 
(clone DO-7; DAKO, Glostrup, Denmark; dilution 1:100), 
and anti-Ki-67 (Lab Vision, Fremont, USA; dilution 1:80). 
We applied anti-FGFR3 overnight in a 4
oC refrigerator and 
anti-Ki-67 and anti-p53 for 1 hour at room temperature. 
DAB chromogen was used.
　FGFR3 protein was expressed in the tumor cell cyto-
plasm or nuclei. Cytoplasmic immunoreactivity was as-
signed scores as follows: 0, negative; 1, weak to moderate; 
and 2, strong. Nuclear expression was defined as positive 
when unequivocal staining was observed regardless of ex-
tent (Fig. 1). Protein expression levels of Ki-67 and P53 
were evaluated by the percentage of positively stained 
nuclei. Cutoffs were defined at 25% and 10% for Ki-67 [14] 
and p53 [9,14], respectively.
　SPSS 12.0 computer software (SPSS Inc., Chicago, USA) 
was used for data analysis. A finding was considered stat-
istically significant at p＜0.05. We examined the following 
variables: demographic data, macroscopic characteristics 
(number, size, and growth pattern), and tumor grade and 
stage. Additionally assessed were the effects of single and 
combined immunohistochemical markers on disease re-
currence. The chi-square test and the two-sided Fisher’s 
exact test were applied to study statistical associations be-
tween measured parameters. The Kaplan-Meier method 
was used to compare curves for the different variables with 
regard to recurrence-free-survival, with significance eval-
uated by log-rank test. Patients were censored at the date 
of first pathological confirmation of recurrent tumor, on the 
date of last follow-up visit, or at the date of death. Cox’s re-
gression analysis was applied to obtain risks of recurrence 
and to find independent prognostic factors.
RESULTS
1. Molecular markers and clinicopathological parameters
The correlation between the molecular markers and tumor 
grade and stage is shown in Table 2. Cytoplasmic FGFR3 
positivity included immunoreactivity type 1 and 2. The ma-
jority (81.3%) of the lower-grade tumors (PUNLMP & Korean J Urol 2010;51:94-100
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TABLE 2. Molecular characteristics related to tumor grade and stage
 
FGFR3-c FGFR3-n Ki-67 P53
Negative Positive p-value Negative Positive p-value Low High p-value Low High  p-value
Total 
Stage 
  Ta
  T1
Grade
  PUNLMP
  Low grade
  High grade
18
(32.7%)
8
10
3 
3
12
37
(67.3%)
30
7
7
19
11
0.011
0.022
37
(67.3%)
25
12
6
17
14
18
(32.7%)
13
5
4
5
9
n.s.
n.s.
35
(63.6%)
29
6
8
20
7
20
(36.4%)
9
11
2
2
16
　0.003
＜0.001
32
(58.2%)
24
8
8
13
11
23
(41.8%)
14
9
2
9
12
n.s.
n.s.
FGFR3: fibroblast growth factor receptor 3, FGFR3-c: cytoplasmic expression of FGFR3, FGFR3-n: nuclear expression of FGFR3, 
PUNLMP: papillary urothelial neoplasm of low malignant potential, n.s.: not significant
FIG. 1. Immunohistochemical expression of FGFR3 in bladder 
cancer. (A) Strong cytoplasmic expression in tumor cells of low- 
grade urothelial carcinoma (x400). (B) Negative cytoplasmic 
FGFR3 reaction in high-grade urothelial carcinoma  (x200). (C) 
Nuclear FGFR3 expression. FGFR3: fibroblast growth factor 
receptor 3 (x400).
low-grade UC) demonstrated cytoplasmic positivity, 
whereas only 47.8% of high-grade urothelial carcinomas 
did (p=0.022). We found that 78.9% of pTa tumors showed 
positive cytoplasmic staining for FGFR3, with 41.2% of pT1 
tumors expressing FGFR3 (p=0.011). Nuclear expression 
was observed in 32.7% of all tumors. There was a tendency 
for tumors without nuclear reactivity to recur more fre-
quently; among the 37 tumors displaying negative nuclear 
reactivity, 48.62% showed recurrence, whereas 22.2% of 
nuclear-positive tumors had recurrences during the fol-
low-up. However, this parameter was not statistically 
significant. A total of 13 tumors (23.6%) showed both cyto-
plasmic and nuclear FGFR3 expression. High Ki-67 re-
activity was noted in 36.4% and tended to be higher as the Korean J Urol 2010;51:94-100
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TABLE 3. Pathological and molecular characteristics related to re-
currence within 2 years
Recurrence within 2 years
Yes No  p-value
Grade
　PULMP
　Low grade
　High grade
Stage 
　Ta
　T1
FGFR3-c
　Negative 
　Positive
FGFR3-n
　Negative 
　Positive 
Ki-67
　Low
　High
P53
　Low
　High
3
4
12
10
9
10
9
16
3
8
11
8
11
7
18
11
29
7
8
27
21
15
27
9
24
12
n.s.
0.036
0.027
n.s.
0.019
n.s.
PUNLMP: papillary urothelial neoplasm of low malignant poten-
tial, n.s.: not significant,  FGFR3: fibroblast growth factor receptor
3, FGFR3-c: cytoplasmic expression of FGFR3, FGFR3-n: nuclear
expression of FGFR3
stage (p=0.003) and grade (p＜0.001) of disease increased. 
We observed p53 overexpression in 41.8% of the tumors; 
however, this was not statistically significant with clin-
icopathological factors.
2. Clinical and molecular characteristics with recurrence 
within two years
Twenty-two patient cases had disease recurrence in their 
clinical course and 19 cases (86.4%) among them recurred 
within 2 years after treatment of primary bladder cancer. 
We analyzed the relationship between clinical and molec-
ular factors and the presence of 2-year recurrence (Table 
3). Tumors with a higher stage, negative cytoplasmic ex-
pression of FGFR3, and high Ki-67 expression demon-
strated more frequent recurrence. However, tumor grade 
and p53 overexpression were not significantly associated 
with recurrence within 2 years.
3. Molecular markers and prediction of recurrence
Kaplan-Meier analyses of recurrence-free survival are 
shown in Fig. 2. Bladder cancer patients with positive cyto-
plasmic or nuclear FGFR3 had significantly better surviv-
al than did patients with FGFR3 negativity. Meanwhile, 
tumors with high expression of Ki-67 or p53 showed sig-
nificantly worse survival than did those with low ex-
pression. Univariate Cox regression analysis showed that 
the recurrence-free interval was significantly shorter in 
older patients and tumors with a higher stage, no cytoplas-
mic expression of FGFR3, high Ki-67 reactivity, and p53 
overexpression (Table 4). However, no parameter proved 
to be an independent predictor of disease recurrence in the 
multivariate model.
DISCUSSION
Germ-line mutations in FGFR3 are well documented in 
skeletal dysplasia syndrome. Frequent somatic mutations 
have been described in multiple myeloma [15], cervical car-
cinoma [16], and bladder cancer [15,17]. A large proportion 
(35-60%) of bladder cancers are found to have mutations 
[14,16], the rate of which was higher in patients with low-
er-grade and lower-stage tumors. The mutation rate was 
75% in low-grade and low-stage cases, but infrequent in 
muscle-invasive diseases [14].
　On the other hand, immunohistochemical expression of 
FGFR3 protein has not been extensively examined to date 
and the exact mechanism of cytoplasmic protein ex-
pression is still unclear. The expression rate is known to 
be between 42% and 80.5% in different grades and stages 
[6,8,18]. Tomlinson et al reported a strong correlation be-
tween expression level and mutation status and tumor 
grade and stage [6]. Two other studies [8,19] using im-
munohistochemistry reported similar relationships, but 
one [18] did not. In our study, cytoplasmic FGFR3 was pos-
itive in 67.3% of all cases and positivity was associated with 
lower grade (p=0.022) and lower stage (p=0.011). This was 
also predictive of recurrence-free survival in the univariate 
analysis (p=0.018), although it failed to remain an in-
dependent predictor in the multivariate model. Barbisan 
et al reported that strong immunohistochemical ex-
pression of FGFR3 was one of the indicators for non-
recurrent papillary urothelial neoplasms of low malignant 
potential [4]. We found no other reports in this regard. In 
mutation studies, the results are not in agreement. Some 
authors [19,20] have reported an association between mu-
tation and a higher recurrence rate, whereas others [14,21] 
have reported the reverse. This discordance is possibly 
caused by differences in patient populations and in tumor 
stratification methods.
　Interestingly, we noticed frequent nuclear reactivity of 
FGFR3 protein in the tumor cells. The nuclear expression 
was observed in 32.7% of the cases and it tended to be ob-
served more frequently in the cases showing recurrences. 
However, it failed to show prognostic power in the Cox re-
gression analysis. Røtterud et al found nuclear staining in 
nearly all carcinoma samples and suggested that FGFR3 
was translocated from the cytoplasm to the nucleus during 
the development of bladder cancer [22]. We could find no 
other reports on the nuclear expression of FGFR3 and its 
relationship to various clinicopathological factors. The 
mechanism related to the nuclear location of FGFR3 pro-
tein remains unclear. Further research is necessary in this 
regard.
　P53 is one of the most frequently studied tumor sup-
pressor genes. Its overexpression and mutations are known Korean J Urol 2010;51:94-100
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TABLE 4. Univariate Cox regression analysis for recurrence-free
survival
Variable Exp (B) 95% CI p-value
Age (years)
Sex 
Multiplicity
Size
Grade
a
Stage
　Ta
　T1
FGFR3-c
FGFR3-n
Ki-67
P53
1.087
0.559
2.312
1.210
2.343
1
2.814
0.336
3.320
3.108
3.117
1.022 to 1.157
0.220 to 1.422
0.534 to 10.013
0.460 to 3.178
0.922 to 5.959
1.138 to 6.963
0.136 to 0.831
0.963 to 11.448
1.245 to 7.759
1.224 to 7.942
0.008
0.222
0.263
0.699
0.074
0.025
0.018
0.057
0.015
0.017
Exp (B): exponential, CI: confidence interval, FGFR3: fibroblast 
growth factor receptor 3, FGFR3-c: cytoplasmic expression of 
FGFR3, FGFR3-n: nuclear expression of FGFR3, PUNLM: papil-
lary urothelial neoplasm of low malignant potential, 
a: lower 
grade (PUNLMP & low grade) vs. higher grade (high grade)
FIG. 2. Kaplan-Meier analyses for recurrence-free survival. (A) Cytoplasmic FGFR3 expression (p=0.012). (B) Nuclear FGFR3 ex-
pression (p=0.042). (C) Ki-67 (p=0.01). (D) p53 (p=0.011). FGFR3: fibroblast growth factor receptor 3.
to be associated with poor clinical outcome in various hu-
man cancers. In bladder cancer, it appears to be related 
with invasive, high-grade carcinoma [23,24]; frequent pro-
gression; and poor survival [21,25,26]. In the aspect of re-
currence, many authors have reported that there is no stat-
istically significant relationship between them, although 
the recurrence rate tends to be increased in patients with 
p53 mutation or altered p53 protein expression [25,26]. 
George et al and Salinas-Sánchez et al did find a significant 
relationship between these same variables [9,10]. In our 
study, p53 overexpression was related with a shorter re-
currence-free survival in the univariate analyses (p= 
0.017) but not in the multivariate model. Malats et al said 
there was a substantial inconsistency in the results on p53 
effectiveness to predict recurrence in the meta-analysis 
[27]. They suggested that the recruitment period, patient 
selection bias, variability in the immunohistochemical as-
says, and different cutoff points were responsible factors 
for these discrepant findings. Differences in study method-
ology and statistical variables might be included among 
those factors.
　We found that high expression of Ki-67 was related to 
higher tumor stage (p=0.003), grade (p＜0.001), and 2-year 
recurrence (p=0.019), but did not have an independent 
prognostic value in terms of tumor recurrence. This result Korean J Urol 2010;51:94-100
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agrees with those of Quintero et al and Yurakh et al, but 
is in contrast with the findings of other researchers 
[26,28,29].
　Given the heterogeneity of urothelial carcinomas, larg-
er-scale studies of Korean patients are necessary in an on-
going work.
CONCLUSIONS
Molecular markers may provide crucial information in pa-
tient management of bladder cancer, which shows highly 
heterogeneous clinical behavior. The FGFR3 mutation is 
known to be related to lower grade and stage in bladder can-
cer and possibly to better patient outcome. Although most 
of the present study focused on mutation analysis, our work 
provides evidence that immunohistochemical expression 
of cytoplasmic FGFR3 is not only one of the characteristic 
features of low-grade and low-stage urothelial carcinoma, 
but also of prognostic value for recurrence-free survival, al-
though it was not an independent marker. We suggest that 
FGFR3 has a high chance of being a useful tool in clinical 
decision making for patient management.
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